LENZ THERAPEUTICS, INC. Depreciation
LENZ THERAPEUTICS, INC. (LENZ) reported Depreciation of $2.40 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. depreciation for the quarter ending 2023-12-31 was $100.00K, a 85.71% decline year-over-year.
- LENZ THERAPEUTICS, INC. depreciation for the quarter ending 2023-09-30 was $800.00K, a 14.29% increase year-over-year.
- LENZ THERAPEUTICS, INC. depreciation for the quarter ending 2023-06-30 was $800.00K, a 33.33% increase year-over-year.
- LENZ THERAPEUTICS, INC. depreciation for the quarter ending 2023-03-31 was $700.00K, a 75.00% increase year-over-year.
- LENZ THERAPEUTICS, INC. depreciation for fiscal 2023 was $2.40M, a 0.00% change from fiscal 2022.
- LENZ THERAPEUTICS, INC. depreciation for fiscal 2022 was $2.40M, a 242.86% increase from fiscal 2021.
- LENZ THERAPEUTICS, INC. depreciation for fiscal 2021 was $700.00K, a 600.00% increase from fiscal 2020.
- LENZ THERAPEUTICS, INC. depreciation for fiscal 2020 was $100.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $900.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.70M derived: sum of 3 quarters · filed 2024-02-27 | $2.40M 10-K · filed 2024-02-27 | |
| 2023-09-30 | $800.00K 10-Q · filed 2023-11-13 | $1.60M derived: sum of 2 quarters · filed 2023-11-13 | $2.30M 10-Q · filed 2023-11-13 | $3.00M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2023-06-30 | $800.00K 10-Q · filed 2023-08-14 | $1.50M 10-Q · filed 2023-08-14 | $2.20M derived: sum of 3 quarters · filed 2024-02-27 | $2.90M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2023-03-31 | $700.00K 10-Q · filed 2023-05-11 | $1.40M derived: sum of 2 quarters · filed 2024-02-27 | $2.10M derived: sum of 3 quarters · filed 2024-02-27 | $2.70M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.40M derived: sum of 2 quarters · filed 2024-02-27 | $2.00M derived: sum of 3 quarters · filed 2024-02-27 | $2.40M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-13 | $1.30M derived: sum of 2 quarters · filed 2023-11-13 | $1.70M 10-Q · filed 2023-11-13 | $2.00M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-14 | $1.00M 10-Q · filed 2023-08-14 | $1.30M derived: sum of 3 quarters · filed 2023-08-14 | $1.50M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-11 | $700.00K derived: sum of 2 quarters · filed 2023-05-11 | $900.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.00M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $500.00K derived: sum of 2 quarters · filed 2022-11-09 | $600.00K derived: sum of 3 quarters · filed 2022-11-09 | $700.00K 10-K · filed 2022-03-21 | |
| 2021-09-30 | $200.00K 10-Q · filed 2022-11-09 | $300.00K derived: sum of 2 quarters · filed 2022-11-09 | $400.00K 10-Q · filed 2022-11-09 | $500.00K derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-11 | $200.00K 10-Q · filed 2022-08-11 | $206.00K 10-Q · filed 2021-08-12 | $300.00K derived: sum of 3 quarters · filed 2022-08-11 | $300.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-12 | $200.00K derived: sum of 2 quarters · filed 2022-05-12 | $200.00K derived: sum of 3 quarters · filed 2022-05-12 | $201.00K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $100.00K derived: sum of 2 quarters · filed 2022-03-21 | $101.00K derived: sum of 3 quarters · filed 2022-03-21 | $100.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $1.00K derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.00K 10-Q · filed 2021-08-12 | $1.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |